{"database":"biostudies-arrayexpress","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown","Transcriptomics","Genomics","Proteomics"],"submitter":["Andrej Besse"],"instrument_platform":["MGISEQ-2000RS"],"study_type":["RNA-seq of coding RNA"],"organism":["Homo sapiens"],"species":["Homo sapiens"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/E-MTAB-15466"],"description":["AMO-1 cell line after 8h of Ceritinib, Carfilzomib treatment and their combination. Cells were continuously treated for 8 h with 4uM Ceritinib and 5nM Carfilzomib. Cell pelets were stored at -80 degree and send on dry ice to BGI company."],"repository":["biostudies-arrayexpress"],"sample_protocol":["Growth Protocol - Cells were grown in RPMI medium supplemented with 10% FBS and anitbiotics","Sample Treatment - Cells were treated with Carfilzomib 5nM or Ceritinib 4uM or combination or without for 8h","Sample Collection - Cell were harvested form T75 flask and washed 2x with PBS and snap frozen in Liquid nitrogen","Library Construction - polyadenylated RNA was enriched using oligo(dT) magnetic beads. First- and second-strand cDNA synthesis was performed using reverse transcriptase and random hexamer primers. After end repair, A-tailing, and adaptor ligation, libraries were amplified by PCR. The final libraries were quality-checked using Qubit and Bioanalyzer before sequencing. Library construction followed BGI’s standard mRNA-seq protocol","Sequencing - Sequencing was performed by BGI using the DNBseq platform, generating paired-end 150 bp reads (PE150). Libraries were circularized, amplified via rolling circle replication to form DNA nanoballs (DNBs), and loaded onto patterned arrays for high-throughput sequencing","Nucleic Acid Extraction - Total RNA was extracted by BGI from the submitted tissue samples using TRIzol reagent or a similar phenol-based method, following their standard RNA extraction workflow. RNA integrity and quantity were assessed using Bioanalyzer or similar QC platforms"],"figure_sub":["Organization","MINSEQE Score","Assays and Data","MAGE-TAB Files"],"pubmed_authors":["Andrej Besse"],"additional_accession":[]},"is_claimable":false,"name":"AMO-1 cell line after 8h of Ceritinib, Carfilzomib treatment and their combination","description":"AMO-1 cell line after 8h of Ceritinib, Carfilzomib treatment and their combination. Cells were continuously treated for 8 h with 4uM Ceritinib and 5nM Carfilzomib. Cell pelets were stored at -80 degree and send on dry ice to BGI company.","dates":{"release":"2025-12-15T00:00:00Z","modification":"2025-12-15T02:01:04.983Z","creation":"2025-08-08T15:19:06.566Z"},"accession":"E-MTAB-15466","cross_references":{"ENA":["ERP178570"],"Biostudies":["E-MTAB-15465"],"EFO":["EFO_0002944","EFO_0004170","EFO_0003789","EFO_0005518","EFO_0003738","EFO_0004184","EFO_0003969"]}}